Early humans may have evolved black skin to protect against a very high risk of dying from ultraviolet light (UV)-induced skin cancer, a new analysis concludes.
Skin cancer has usually been rejected as the most likely selective pressure for the development of black skin because of a belief that it is only rarely fatal at ages young enough to affect reproduction.
But a new paper, published in Proceedings of the Royal Society B, cites evidence that black people with albinism from parts of Africa with the highest UV radiation exposure, and where humans first evolved, almost all die of skin cancer at a young age.
The paper, by Professor Mel Greaves at The Institute of Cancer Research, London, cites studies showing that 80 per cent or more of people with albinism from African equatorial countries such as Tanzania and Nigeria develop lethal skin cancers before the age of 30.
Albinism is also linked to skin cancer in indigenous populations of other tropical countries with high, year-round UV exposure such as Panama.
Professor Greaves argues that the fact that people with albinism, which is caused by genetic changes that prevent the production of melanin, develop cancer at reproductive ages is indirect but persuasive evidence that early, pale-skinned humans were under strong evolutionary pressure to develop melanin-rich skin in order to avoid lethal skin cancer.
Genetic evidence suggests that the evolution of skin rich in eumelanin, which is brown-black in colour, occurred in early humans between 1.2 and 1.8 million years ago in the East African Savannah. Early humans having lost most of their body hair (probably to facilitate heat loss) probably had pale skin containing pheomelanin - like our nearest surviving relatives, chimpanzees. Pheomelanin, characteristic of white skin, is red-yellow and packaged into smaller stores under the skin than eumelanin, characteristic of black skin. Eumelanin provides a much more effective barrier against the DNA damage that causes skin cancers, providing almost complete protection.
Most scientists agree the development of black skin occurred in early humans primarily because of the ability of eumelanin to effectively absorb ultraviolet radiation, but they have debated exactly how this could have protected early humans against lethal diseases.
As well as affecting skin cancer risk, increased black melanin production could have given other benefits that helped individuals to pass on their genes to the next generation, such as preventing damage to sweat glands or the destruction of folate, which is important in foetal development.
While there could have been many benefits of having black skin in Africa (and retaining it in New Guinea), Professor Greaves argues that individuals with albinism and no protective benefit from melanin almost all die young from cancer.
Professor Greaves is Director of the new Centre for Evolution and Cancer at The Institute of Cancer Research (ICR). The Centre aims to gain new insights into how individual cancers evolve – the process behind the development of drug resistance, and the often extraordinary genetic diversity within single tumours – and to uncover clues in our evolutionary history that could help us understand why human cancers develop.
Professor Mel Greaves, Director of the Centre for Evolution and Cancer at The Institute of Cancer Research, London, said:
“Charles Darwin thought variation in skin colour was of no adaptive value and other investigators have dismissed cancer as a selective force in evolution. But the clinical data on people with albinism, particularly in Africa, provide a strong argument that lethal cancers may well have played a major role in early human evolution as an important factor in the development of skin rich in dark pigmentation - in eumelanin.”
Source: ICR
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.